Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.

ABSTRACT: Advanced-stage cancers often metastasize to bone, and is the major cause of cancer-related morbidity and mortality. Due to poor biodistribution of intravenously administered anticancer drugs within the bone, chemotherapy is not optimally effective in treating bone metastasis. Additionally, overexpression of receptor activator of nuclear factor κB ligand (RANKL) in the bone microenvironment drives the vicious, destructive cycle of progression of bone metastasis and bone resorption. We hypothesized that the combination treatment - with docetaxel (TXT), an anticancer drug encapsulated in sustained release biodegradable nanoparticles (TXT-NPs) that are designed to localize in bone marrow, and denosumab monoclonal antibody (DNmb), which binds to RANKL - could be more effective than either treat

SUBMITTER: Vijayaraghavalu S 

PROVIDER: S-EPMC6870877 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature